Diverse antigen binding domains, novel platforms and other enhancements for cellular therapy
AssigneeAngeles Therapeutics, Inc.
InventorPreet M. Chaudhary
Life of this patent
Estimating the term…
Abstract
The disclosure provides diverse antigen binding domains and platforms for construction of conventional and next generation chimeric antigen receptors for adoptive cellular therapies for cancer, infection, allergic, degenerative and immune disorders, Also provided are approaches for activation and expansion of immune T cells for adoptive cellular therapies for cancer, infection, allergic, degenerative and immune disorders.
Claims20
At least one recombinant polynucleotide encoding a synthetic immune receptor-CD3-zeta (zSIR) heterodimer comprising two CD3-zeta (CD3z) chains,
- wherein each CD3z chain comprises the transmembrane domain and cytoplasmic domain of a CD3z protein;
- wherein a variable light (vL) domain of an antibody is operably linked to a first of the two CD3z chains via a first linker and a variable heavy (vH) domain of the antibody is operably linked to a second of the two CD3z chains via a second linker;
- wherein the first linker comprises an IgCL domain and the second linker comprises an IgCH domain;
- and wherein the vL domain and the vH domain are from the same antibody and together bind a target antigen recognized by the antibody.
A synthetic immune receptor-CD3-zeta (zSIR) polypeptide heterodimer comprising two CD3-zeta (CD3z) chains, wherein each CD3z chain comprises the transmembrane domain and cytoplasmic domain of a CD3z protein;
- wherein a variable light (vL) domain of an antibody is operably linked to a first of the two CD3z chains via a first linker and a variable heavy (vH) domain of the antibody is operably linked to a second of the two CD3z chains via a second linker;
- wherein the first linker comprises an IgCL domain and the second linker comprises an IgCH domain;
- and wherein the vL domain and the vH domain are from the same antibody and together bind a target antigen recognized by the antibody.
Dependencies are inferred from the claim text.